



## Review

# A New Algorithm for the Diagnosis of Hypertension in Canada

Lyne Cloutier, RN, PhD,<sup>a</sup> Stella S. Daskalopoulou, MD, PhD,<sup>b</sup> Raj S. Padwal, MD, MSc,<sup>c</sup> Maxime Lamarre-Cliche, MD,<sup>d</sup> Peter Bolli, MD,<sup>e</sup> Donna McLean, RN, NP, PhD,<sup>f</sup> Alain Milot, MD, MSc,<sup>g</sup> Sheldon W. Tobe, MD, MSc(HPTE),<sup>h</sup> Guy Tremblay, MD,<sup>i</sup> Donald W. McKay, PhD,<sup>j</sup> Raymond Townsend, MD,<sup>k</sup> Norm Campbell, MD,<sup>l</sup> and Mark Gelfer, MD<sup>m</sup>

<sup>a</sup>Department of Nursing, Université du Québec à Trois-Rivières, Trois-Rivières, Québec, Canada

<sup>b</sup>Divisions of General Internal Medicine and Experimental Medicine, Department of Medicine, McGill University, Montréal, Québec, Canada

<sup>c</sup>Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

<sup>d</sup>Institut de Recherches Cliniques de Montréal, Université de Montréal, Montréal, Québec, Canada

<sup>e</sup>Ambulatory Internal Medicine Teaching Clinic, St Catharines, Ontario, Canada

<sup>f</sup>University of Alberta, Edmonton, Alberta, Canada

<sup>g</sup>Department of Medicine, Université Laval, Québec, Québec, Canada

<sup>h</sup>University of Toronto, Toronto, Ontario, Canada

<sup>i</sup>CHU-Québec-Hopital St Sacrement, Québec, Québec, Canada

<sup>j</sup>Faculty of Medicine, Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada

<sup>k</sup>University of Pennsylvania, Philadelphia, Pennsylvania, USA

<sup>l</sup>Department of Medicine, University of Calgary, Calgary, Alberta, Canada

<sup>m</sup>Department of Family Medicine, University of British Columbia, Copeman Healthcare Centre, Vancouver, British Columbia, Canada

**See editorial by Spence, pages 580-582 of this issue.**

## ABSTRACT

Accurate blood pressure measurement is critical to properly identify and treat individuals with hypertension. In 2005, the Canadian Hypertension Education Program produced a revised algorithm to be used for the diagnosis of hypertension. Subsequent annual reviews of the literature have identified 2 major deficiencies in the current diagnostic process. First, auscultatory measurements performed in routine clinical settings have serious accuracy limitations that have not

## RÉSUMÉ

L'exactitude de la mesure de la pression artérielle est essentielle pour identifier et traiter correctement les individus atteints d'hypertension artérielle. En 2005, le Programme éducatif canadien sur l'hypertension a produit un algorithme révisé à utiliser pour le diagnostic de l'hypertension. Les révisions annuelles subséquentes de la littérature ont identifié 2 lacunes importantes dans le processus actuel de diagnostic. Premièrement, les mesures auscultatoires réalisées

Hypertension affects an estimated 7.3 million Canadians<sup>1,2</sup> and is the most common modifiable risk factor for death or disability in the world.<sup>3</sup> If not identified and treated, hypertension will invariably lead to complications affecting

numerous organ systems including the brain, heart, eyes, kidneys, and the peripheral vasculature. Control of hypertension in Canada has improved markedly in the past 15 years with a 5-fold increased rate of control observed, from 13.2% in 1992 to 64.6% in 2007.<sup>4</sup> However, one-third of the hypertensive population remains uncontrolled and 17% remain unaware that they have hypertension.

Accurate blood pressure (BP) measurement is essential to properly identify and treat individuals with hypertension. Office BP has been traditionally measured by nurses or doctors using auscultatory methods, with 4 to 5 visits required to

Received for publication January 14, 2015. Accepted February 16, 2015.

Corresponding author: Dr Lyne Cloutier, Département des sciences infirmières, Université du Québec à Trois-Rivières, 3351 Boulevard des Forges, Trois-Rivières, Québec G9A 5H7, Canada. Tel.: +1-819-376-5011 ×3466; fax: +1-819-376-5048.

E-mail: [lyne.cloutier@uqtr.ca](mailto:lyne.cloutier@uqtr.ca)

See page 626 for disclosure information.

been overcome despite great efforts to educate health care professionals over several years. Thus, alternatives to auscultatory measurements should be used. Second, recent data indicate that patients with white coat hypertension must be identified earlier in the process and in a systematic manner rather than on an ad hoc or voluntary basis so they are not unnecessarily treated with antihypertensive medications. The economic and health consequences of white coat hypertension are reviewed. In this article evidence for a revised algorithm to diagnose hypertension is presented. Protocols for home blood pressure measurement and ambulatory blood pressure monitoring are reviewed. The role of automated office blood pressure measurement is updated. The revised algorithm strongly encourages the use of validated electronic digital oscillometric devices and recommends that out-of-office blood pressure measurements, ambulatory blood pressure monitoring (preferred), or home blood pressure measurement, should be performed to confirm the diagnosis of hypertension.

establish the diagnosis.<sup>5</sup> Standardized measurement methods were proposed to clinicians in 1984 by the Canadian Hypertension Society and in 1999 by the Canadian Hypertension Education Program (CHEP) to guide the performance of these measures.<sup>6</sup> In 2005, out-of-office measurements using ambulatory BP measurement (ABPM) or home BP measurement (HBPM) were added to the CHEP algorithm to complement OBPM.<sup>7,8</sup>

A reappraisal of the CHEP recommendations to diagnose hypertensive patients is imperative because of 2 main shortfalls in the current algorithm. First, office auscultatory measurements performed in routine clinical settings have serious limitations that have not been overcome despite great efforts to educate health care professionals over several years. Second, recent data indicate that patients with white coat hypertension (WCH; ie, not truly hypertensive) should be identified earlier in the process and in a systematic manner rather than on an ad hoc or voluntary basis so they are not unnecessarily treated with antihypertensive medications.

We present evidence for the need to de-emphasize the use of routine auscultatory OBPM and encourage use of electronic digital devices, and evidence for preferentially using more accurate and reproducible out-of-office methods for earlier and systematic detection of WCH. A revised algorithm (Fig. 1) for the diagnosis of hypertension is introduced. HBPM and ABPM protocols will be reviewed, and the role of automated office BP (AOBP) updated.

### New Algorithm

In our new algorithm we strongly recommend performing out-of-office measurement (ABPM or HBPM) after the first visit, specifically to identify patients with WCH early in the process. Another important addition to the algorithm concerns AOBP, which has been shown to reduce the white-coat


dans le cadre de la pratique clinique courante montrent de sérieuses limites d'exactitude qui n'ont pas été surmontées en dépit de grands efforts depuis plusieurs années pour former les professionnels de la santé. Par conséquent, les solutions de rechange aux mesures auscultatoires soit des mesures électroniques oscillométriques devraient être utilisées. Deuxièmement, de récentes données montrent que les patients souffrant d'hypertension de sarrau blanc doivent être identifiés plus tôt au cours du processus et de manière systématique plutôt que sur une base ponctuelle ou volontaire afin d'éviter qu'ils ne soient pas traités inutilement par des antihypertenseurs. Les conséquences sur le plan économique et de la santé de l'hypertension de sarrau blanc sont décrites dans le texte. Dans le présent article, nous présentons les résultats probants concernant un algorithme révisé pour diagnostiquer l'hypertension artérielle. Nous révisons les protocoles de la mesure de la pression artérielle à domicile et du monitoring ambulaire de la pression artérielle ambulatoire de la pression artérielle. Nous traitons du rôle des mesures de la pression artérielle en clinique - oscillométriques en série. L'algorithme révisé encourage fortement l'utilisation des appareils de mesure oscillométriques validés à capteur électronique et lecture numérique, et recommande que les mesures de la pression artérielle en ambulatoire, le monitoring ambulaire de la pression artérielle (préférée) ou la mesure de la pression artérielle à domicile à domicile soient réalisées pour confirmer le diagnostic d'hypertension.

effect, and, thus the number of patients who will require further assessment with ABPM or HBPM.<sup>9</sup> AOBP implies multiple oscillometric measurements taken while the patient is alone in a quiet room. The mean of these measurements is used to make clinical decisions.

In patients who do not have severely increased BP on visit 1 ( $\geq 180/110$  mm Hg), serial standardized OBPMs have been retained as a potential pathway to arrive at the diagnosis of hypertension. However, this method is cumbersome because it requires 4 or 5 visits over 6 months to be truly certain that the BP level is increased.<sup>5</sup> We emphasize that out-of-office measurement is preferred to serial standardized office measurement—the latter should be used only when the resources (human, technical, or financial) to perform out-of-office measurement are not available.

### Diagnosis of Hypertension in Canada From 1999 to 2005

The approach to the diagnosis of hypertension has evolved since the Canadian recommendations for the management of hypertension first proposed a systematic approach to diagnose hypertension based on clinic BP measurement in 1999.<sup>10</sup> These initial recommendations indicated that patients who present with hypertensive urgency ( $\geq 180/105$  mm Hg) could be diagnosed at the first visit, patients with increased BP readings and target organ damage (TOD) could be diagnosed at/after the third visit, and all other patients with clinic BP between 140/90 and 180/105 mm Hg would require at least 4 further visits over the next 6 months to be diagnosed with hypertension. This recommendation was supported by studies that showed that the number of visits at which clinic BP is assessed and the duration of the observation period are important because BP tends to decrease over the course of several visits.<sup>11-15</sup>



**Figure 1.** Diagnostic algorithm for hypertension. BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.

In 2004, this approach was modified to allow patients without TOD and/or increased cardiovascular risk to be diagnosed at the third visit if clinic BP remained  $\geq 160/100$  mm Hg, because the greatest decrease in BP was shown to occur between visit 1 and 2.<sup>16</sup> If the BP at visit 3 was 140-159/90-99 mm Hg, up to 3 additional visits over a total assessment period of 6 months were still required to diagnose a patient as hypertensive.<sup>17-19</sup> In the 2015 algorithm, after 2 visits including the use of out-of-office measurements, a diagnosis of hypertension can be established.

In 2005, the CHEP, recognizing the accumulation of prognostic evidence in favour of ABPM and HBPM, recommended the addition of these measurement methods as alternative pathways to expedite the diagnosis of hypertension after the second visit.<sup>8</sup> Since 2005, for uncomplicated patients (absence of TOD or diabetes mellitus with average BP of 140-179/90-109 mm Hg after 2 visits), 3 approaches to diagnose hypertension could be taken: repeated OBPMs over the next several weeks to months, 24-hour ABPM, or HBPM. Using the latter 2 out-of-office modalities, clinicians could diagnose uncomplicated hypertension earlier (at the third visit) rather than taking up to 5 visits over 6 months with repeated OBPM.

#### Limitations of Routine OBPM

Benefits in terms of decreased morbidity and mortality from cardiovascular and cerebrovascular causes can be derived

by achieving and sustaining published BP targets. In hypertension management, this largely relies on an accurate measurement and proper subsequent evaluation.<sup>20</sup> Many investigators over the past 4 decades have studied the errors observed in routine office auscultatory measurement, in nurses and in physicians, because of issues concerning the observer, the preparation of the patient, the technique, and the device used.<sup>21-29</sup> In addition, studies concerning the knowledge and practice of doctors and nurses have clearly demonstrated that there are serious deficiencies in all areas despite extensive and repeated educational programs in the initial education of health care professionals and through continuous professional education activities.<sup>22,30-35</sup> Accurate OBPM when properly performed in a standardized method (sometimes called “research-quality OBPM”), correlates well with ambulatory measurements and can predict target organ changes.<sup>36-38</sup> Unfortunately, there is overwhelming evidence that truly standardized OBPMs are not usually performed in routine clinical practice. Indeed, comparisons of BP research-quality manual BP readings with routine manual BP in a number of studies have shown that the BP obtained in routine clinical practice is on average 9/6 mm Hg higher than corresponding research-quality BP measurements.<sup>39,40</sup>

“Routine” or “casual” (ie, nonstandardized) BP measurements should never be used to diagnose a patient as hypertensive or to follow a patient’s progress. Examples of deviations from standardized protocols include among others measurement of BP in patients without a rest period, while

conversing, with the back unsupported, and legs crossed. Although this is not a new recommendation, it is imperative to stress this issue because nonstandardized BP measurements are still widely performed.

In place of auscultatory OBPM we strongly encourage the use of validated electronic digital oscillometric devices. These devices are preprogrammed to take either single measurements or an automated series of measurements with averaging of the results. Electronic oscillometric digital BP measurement has been available for many years, and has been shown to decrease a number of errors linked to auscultation measurement ranging from clinicians' hearing deficits, rounding errors to 0 or 5, improper use of diaphragm or bell, improper use of Korotkoff sounds, and rapid deflation.<sup>41,42</sup> Using published validation protocols, many devices for clinical and public use have been found to be accurate and reproducible compared with research-quality OBPM ([www.dableducational.com](http://www.dableducational.com)). For these reasons, we strongly recommend that electronic oscillometric digital device methods should be used for OBPM. Electronic oscillometric digital devices will reduce terminal digit preference,<sup>36,39,43</sup> however, a study performed in Switzerland demonstrated that terminal digit preference can still occur with the use of these devices when BP values are transferred onto case report forms.<sup>44</sup> Thus, care must be taken to record the readings exactly as calculated by the device. The protocol for OBPM with an electronic oscillometric digital device is presented in [Table 1](#).

There might be an argument for using an auscultation method in the office in the case of arrhythmias, such as atrial fibrillation when an automated device might have difficulty, although there is evidence that the auscultation method has similar difficulties.<sup>45</sup> Recent published studies have shown that most electronic oscillometric digital devices measure systolic BP just as accurately as auscultation methods in patients with atrial fibrillation, with diastolic BP measured slightly higher on average.<sup>46-48</sup>

### **AOBP Can Overcome OBPM Limitations**

AOBP measurement is a specific type of OBPM designed to overcome some of the limitations of OBPM. Multiple (3-6, depending on the device) measurements, usually spaced 1 minute apart over 4-7 minutes, are taken while the patient is alone in a quiet room. The patient must be sitting quietly

with legs uncrossed, back supported, and with arm supported at heart level. The proper cuff has to be selected as proposed by the manufacturer. AOBP devices are preprogrammed to take serial oscillometric BP measurements and are currently used in many Canadian clinical settings. To be recognized as true AOBP, all of these conditions must be met. The mean of these measurements is used to make clinical decisions. Commonly used devices include the BpTRU (BpTRU Medical Devices, Coquitlam, Canada), Omron HEM 907 (Omron Corporation, Kyoto, Japan), and the MicroLife WatchBP Office (Microlife, Widnau, Switzerland).

AOBP provides a more standardized assessment of BP compared with routine manual office measurement and is more reproducible than manual office measurement. Because the patient is left alone, error introduced by conversing with the patient during the measurement process is eliminated.<sup>49,50</sup> Importantly, compared with manual office measurements, AOBP has repeatedly been demonstrated to correlate closely with daytime ABPM.<sup>9,40,51-54</sup>

Furthermore, use of AOBP reduces office-induced BP increases (ie, white coat effect) and is associated with a lower prevalence of masked hypertension.<sup>9,53</sup> On the basis of this evidence, the CHEP Recommendations Task Force endorsed the use of AOBP for OBPM in 2011.<sup>55</sup>

Three cross-sectional studies demonstrating high correlations between AOBP levels and surrogate measures of end-organ damage (left ventricular mass index, urinary albumin excretion, and carotid intima-medial thickness) have been published.<sup>56-58</sup> Although these surrogate marker studies provide evidence to support the use of AOBP, additional and more definitive data are needed and such studies should be considered a top research priority. AOBP can be used for assessment of BP in the office although the diagnosis of hypertension cannot be solely based on this method until high-quality prognostic data demonstrate strong, independent, and graded relationships between increasing AOBP levels and incident cardiovascular morbidity and/or mortality events. When using AOBP, an average reading of  $\geq 135/85$  can be considered as high.

### **WCH: The Primary Reason to Perform Out-of-Office Measurement**

WCH is defined as increased OBPM ( $\geq 140/90$  mm Hg) with normal out-of-office readings ( $< 135/85$  mm Hg)

**Table 1. Office BP measurement protocol**

1. Measurements should be taken with a sphygmomanometer known to be accurate. A validated electronic device should be used
2. Choose a cuff with an appropriate bladder size matched to the size of the arm. When using an automated device, select the cuff size using the marks, as recommended by its manufacturer
3. The patient should be resting comfortably for 5 minutes in the seated position with back support
4. Place the cuff so that the bladder is centred over the brachial artery. The arm should be bare and supported with the BP cuff at heart level, because a lower position will result in an erroneously higher SBP and DBP. The patients' legs should not be crossed
5. There should be no talking during measurement
6. Press the start button. The first reading should be discarded and the latter 2 averaged
7. BP should also be assessed after 2 minutes of standing (with arm supported) and at times when patients report symptoms suggestive of postural hypotension. Supine BP measurements might also be helpful in the assessment of elderly and diabetic patients
8. Record the BP displayed and the arm used and whether the patient was supine, sitting, or standing. Record the heart rate
9. The seated BP is used to determine and monitor treatment decisions. The standing BP is used to examine for postural hypotension, if present, which might modify the treatment
10. BP should be taken in both arms on at least 1 visit and if 1 arm has a consistently higher pressure, that arm should be subsequently used for BP measurement and interpretation

BP, blood pressure; DBP, diastolic BP; SBP, systolic BP.

daytime ABPM or HBPM and/or  $< 130/80$  mm Hg for 24-hour ABPM). A meta-analysis of 4 population studies found a prevalence of WCH of 13% with a range of 9%-16%.<sup>59</sup> Recently, this prevalence has been challenged and some authors indicate that WCH occurs in up to 30% of subjects with increased office BP readings.<sup>60,61</sup> The likelihood of having WCH is greater in women, older subjects, nonsmokers, subjects recently diagnosed with hypertension with a limited number of routine OBPMs, subjects with mild hypertension, pregnant women, and subjects without evidence of TOD. The white coat phenomenon has been shown to be reasonably reproducible.<sup>62-64</sup>

In 4 meta-analyses, WCH has been shown to have an overall risk of cardiovascular events similar to normotension.<sup>61,65-67</sup> However, one other meta-analysis of the International Database of Home BP in Relation to Cardiovascular Outcome (IDHOCO) found an increased event rate among adults with WCH (adjusted hazard ratio, 1.42; 95% confidence interval, 1.06-1.91).<sup>67</sup> It has been suggested that WCH is associated with a greater risk of developing sustained hypertension in the next decade, as shown in the Pressione Arteriose Monitorate E Loro Associazioni (PAMELA) and Ohasama studies, and that subjects with WCH might have greater left ventricular mass index compared with normotensive subjects.<sup>68,69</sup> However, in these studies participants with WCH had other cardiovascular risk factors. Subjects with WCH have been shown to be more likely to progress to sustained hypertension if they also have high-normal awake ABPM, additional cardio-metabolic risk factors, or increased nighttime ABPM.<sup>61</sup> The clinical bearing of WCH is not fully comprehended probably in part because of the presence of significant heterogeneity across studies that assessed its prognosis. Studies differ with respect to population characteristics, inclusion of treated and/or untreated participants, protocol for OBPM, reference out-of-office BP monitoring method, cutoff values used, and the duration of follow-up.<sup>70</sup>

The diagnosis of hypertension using OBPM alone can misclassify patients who do not have hypertension (WCH).<sup>43,71,72</sup> Every day, more than 1000 people are newly diagnosed in Canada as hypertensive. BP assessment using OBPM alone will daily misdiagnose approximately 100 patients with WCH as hypertensive (36,500 annually).<sup>73</sup> This estimate is conservative and the actual number of patients with WCH misdiagnosed as hypertensive might be even higher. Many of these patients will be treated unnecessarily with antihypertensive medications. Currently, there is no evidence to support pharmacologic treatment of subjects with WCH.<sup>61,74-76</sup> In subjects with WCH, it has been shown that antihypertensive treatment might decrease OBPM but not ABPM and second that unnecessary treatment might lead to partial reduction in white coat effect but with cardiovascular risk similar to the normotensive comparator group. It has also been shown in subjects with WCH that the influence of treatment on electrocardiogram voltages and on the incidence of stroke and cardiovascular events is similar to placebo.<sup>61,74-76</sup> Importantly, treated and untreated subjects with WCH were noted to have similar long-term cardiovascular risk compared with treated and untreated normotensive subjects, respectively.<sup>61</sup>

A false diagnosis of hypertension in people with WCH can also have a significant effect on actual or future employability,

and workplace issues, such as absenteeism.<sup>61</sup> If long-term antihypertensive treatment is initiated, there will be unnecessary costs and potential adverse side effects.

WCH is not entirely benign, therefore it is critical for patients with WCH to be identified early so that lifestyle improvements can be instituted where necessary, and they can be followed closely. Left untreated, some patients with WCH will develop hypertension over time<sup>68,69</sup> or might have higher left ventricular mass index compared with normotensive subjects.<sup>77</sup> Patients at greater risk for progression include those with increased ABPM nighttime average and patients with high-normal ABPM daytime average, especially the middle-aged, elderly, and those with associated metabolic risk factors.

By definition, OBPM alone cannot determine WCH. The diagnosis of WCH must be made by comparing out-of-office BP with office BP measurements. ABPM and HBPM have been shown to be effective in diagnosing WCH, and both methods have been shown to be more strongly associated with cardiovascular outcomes than OBPM.<sup>65,78-87</sup>

There is a larger body of evidence for ABPM than HBPM with respect to prediction of TOD but the evidence for HBPM has been growing in recent years.<sup>88</sup> The diagnostic agreement between ABPM and HBPM has been shown to be moderate and it has been suggested that the 2 methods are to a certain extent complementary.<sup>89</sup> ABPM was found to predict silent cerebrovascular lesions better than HBPM, and HBPM was more closely associated with the risk of carotid atherosclerosis than ABPM.<sup>90</sup> However, HBPM has been shown to correlate similarly with ABPM with left ventricular mass index, but better than OBPM; the evidence for other TOD markers is limited.<sup>91</sup>

It has been suggested that HBPM showing borderline WCH should be confirmed with ABPM<sup>88</sup> or with a second set of HBPM measures.<sup>83,92-95</sup> If WCH is shown (ie, increased OBPM and normal out-of-office BP measurement), the out-of-office measurement should be used by health care practitioners to guide diagnosis and management of hypertension.

## Economic Analyses

Several published reports have demonstrated the economic argument for identifying WCH before making a diagnosis of hypertension. The most recent systematic review<sup>96</sup> identified 14 published cost-effectiveness studies—9 clinical trials and 5 model-based decision analyses. Nine studies compared ABPM with OBPM alone, 4 compared HBPM with OBPM, and 1 compared all 3 methods. In most (8 of 9) studies that compared ABPM with OBPM investigators found short-term (lower medication costs from not treating patients with WCH) and long-term (decreased overall treatment costs) savings over 1-7 years for hypertension diagnosis confirmation using ABPM. Only one observational trial<sup>97</sup> showed a small increased cost over 1 year. For HBPM compared with OBPM the evidence is not as robust but 1 of 2 randomized controlled trials and 3 of 4 modelling analyses showed a cost benefit. The only modelling analysis that examined all 3 methods<sup>98</sup> concluded, "ABPM is cost effective compared with further monitoring in the clinic or home for confirming the diagnosis of hypertension in a population with suspected BP greater

than 140/90 mm Hg on the basis of a clinic screening measurement.”

An extensive cost-benefit analysis that examined ABPM and HBPM vs OBPM for the diagnosis of hypertension was published by the UK National Institute for Clinical Excellence.<sup>99</sup> This analysis concluded that confirming a diagnosis of hypertension with ABPM instead of OBPM or HBPM was the most cost-effective option in all age/sex subgroups. In addition, “In most subgroups ABPM was associated with higher quality-adjusted life years... as well as lower costs, than OBPM and HBPM,” (that is, ABPM was the dominant option). The National Institute for Clinical Excellence determined that, “Under real world conditions, the use of a 24-hour ABPM device would reduce inappropriate treatment of patients with WCH. The key driver of cost savings with ABPM compared with OBPM was hypertension treatment costs avoided due to more accurate diagnosis (increased specificity).”<sup>99</sup>

In a Canadian context, the Ontario Health Technology Assessment Centre (OHTAC)<sup>100</sup> investigated the cost-effectiveness of using ABPM to confirm the diagnosis when OBPM is increased, “considering that over \$2.3 billion (Can) were spent on hypertension in Canada in 2003 (physician, medication, and laboratory costs), reducing or eliminating the population of white coat hypertensive individuals who might inappropriately be treated would potentially result in cost savings on multiple levels of the health care system.” Based on their literature review, the OHTAC group found in the short-term that patients diagnosed using ABPM were more likely to have control of BP and to discontinue drug therapy. The OHTAC analysis concluded that the budget effect in Ontario over the next 5 years (ie, FY2011-FY2015) of providing 24-hour ABPM to patients only for increased BP readings, or when BP is not in control, is a cost savings of approximately \$19 million (Can) per year. However, if the test is given once annually to anyone suspected of having hypertension, the budget effect is an additional \$37 million (Can) per year.

Considering the importance of WCH, the serious limitations of auscultatory OBPM and the importance of identifying hypertension correctly but in a timely manner, it is crucial at this time to update the diagnostic algorithm.

## **ABPM Method, Reporting, and Interpretation**

### **Method**

ABPM has certain advantages, including the requirement for minimal subject training, and importantly its ability to provide nighttime BP measurement. This is particularly important because there is increasing evidence supporting that nighttime BP is an important predictor of cardiovascular events, and according to some studies, even more important than daytime or 24-hour ABPM.<sup>78,90,101-104</sup> Several pathophysiological mechanisms have been proposed to be implicated in the occurrence of cardiovascular events with higher nighttime BP, including disturbed baroreflex sensitivity, alterations in the sympathetic modulation of the nighttime BP, sleep apnea, increased salt sensitivity necessitating a higher BP at night to drive pressure natriuresis, and nighttime BP is better standardized than the daytime BP in terms of physical and mental activity and body position.<sup>101</sup>

Similar to other methods of BP measurement, ABPM must be performed in a standardized manner. A validated upper arm device must be used and the appropriate sized cuff<sup>29</sup> should be applied to the nondominant arm unless the systolic BP difference between arms is > 10 mm Hg, in which case the arm with the highest value obtained should be used.<sup>105</sup> The device should be set to record for a duration of at least 24 hours,<sup>78,106-115</sup> and the measurement frequency set at 20-30 minute intervals during the day, and 30-60 minute intervals during the night.<sup>78,106,107,110,112-114</sup> A patient-reported diary to define daytime (awake) and nighttime (sleep) activities, symptoms, and medication administration is preferable for study interpretation. Alternatively, predefined thresholds can be used; for example, defining the daytime period as 0800 hours to 2200 hours and nighttime as 2200 hours and 0800 hours.

### **Reporting of ABPM results**

The ABPM report, preferably displayed on a single page, should include all of the individual BP readings (numerically and graphically), the percentage of successful readings, the weighted averages for each time frame (daytime, nighttime, 24-hour), and the “dipping” percentage (the percentage decrease in average nighttime BP from average daytime BP—normally between 10% and 20%). The time frame averages can be calculated automatically by the device software, however there is some difficulty making assumptions regarding the actual awake and sleep time periods for individual subjects. Some of the newer devices are equipped with accelerometers, which might facilitate this in the future. The report should also include either an automated interpretation or space for an expert interpretation to be added.

### **Interpretation of ABPM reports**

An ABPM test is considered successful if at least 70% of the readings are valid and at least 20 daytime readings and 7 nighttime readings are valid. The threshold for diagnosis of hypertension is a daytime average of  $\geq 135/85$  mm Hg or 24-hour average of  $\geq 130/80$  mm Hg. Recent literature shows the critical importance of increased nighttime average and “nondipping” (ie, < 10% decrease in average nighttime BP from average daytime BP) as predictors of increased cardiovascular disease risk, so the 24-hour average might be more advantageous because it includes the nighttime period. Many ABPM reports include a “BP load” percentage for systolic and diastolic BP, but the evidence supporting the interpretation of BP load remains limited, and currently it is useful only for research purposes.

### **HBPM Diagnostic Series**

Over the years, increased HBPM use has been undeniably linked to its powerful predictive value in the occurrence of cardiovascular events for morbidity and mortality. Prospective studies have led to a better understanding of the predictive power of HBPM compared with clinic-based measurements.<sup>78,81,87,90,101,102,116</sup> Ward et al. concluded in a recent meta-analysis of prospective studies in which the relationship of HBPM with cardiovascular disease was reported that

HBPM is a significant predictor of cardiovascular mortality and cardiovascular events after adjusting for office BP.<sup>87</sup>

HBPM has a singular capacity that differentiates it from other types of BP measurement. It helps patients to better control their hypertension<sup>117,118</sup> and increases therapeutic adherence.<sup>119</sup> Moreover, the acceptance of the public of HBPM is remarkable.<sup>120</sup> Manufacturers and suppliers have witnessed explosive sales of HBPM devices.<sup>121,122</sup> From a population health perspective, the motivation of patients to become involved in follow-up of their chronic diseases such as hypertension is outstanding news. However, the popularity of HBPM means that health care professionals need to be prepared to guide patients in best practices. Like other BP measurement methods, HBPM can be performed incorrectly, and the risk of reporting bias is increased. However, proper education on HBPM can improve its performance.<sup>123</sup>

For several years the CHEP has been publishing recommendations on how to perform HBPM correctly for the purpose of diagnosing hypertension (HBPM diagnostic series) and these recommendations remain unchanged—using a validated upper arm electronic device with the correct cuff size, take 2 readings in the morning and evening approximately 1 minute apart for 7 days. The first-day readings are discarded and the remaining readings are averaged. If the average is  $\geq 135/85$  mm Hg, a diagnosis of hypertension is made.

### Future Revisions of the Algorithm

The role of AOBP in the diagnosis and follow-up of hypertension requires further assessment. This is currently under study through a CHEP-initiated grant.<sup>124</sup> Other issues that are under review include the need for guidance on how to identify and diagnose patients with masked hypertension and whether a lack of nocturnal dipping should be targeted with bedtime administration of antihypertensive drugs.

### Conclusion and Recommendations

Many patients in Canada are currently being misdiagnosed as hypertensive on the basis of increased manual “routine” office BP readings. In the real-world setting of clinical practice, most of these manual office BP readings are poorly performed using auscultatory techniques.<sup>125</sup> Evidence supports the use of electronic oscillometric digital BP measurements in the office setting and the need for out-of-office BP measurements using ABPM or an HBPM diagnostic series to corroborate increased BP readings performed in the office or clinic setting to properly diagnose hypertension (ie, identify WCH). Because the cardiovascular risk for WCH has been shown to be similar to that of normotensive comparator groups, there is no evidence to support pharmacologic treatment in subjects with WCH at the present time. Misdiagnosing patients with WCH as hypertensive might have important negative implications at the individual and the health care system level.

### Funding Sources

The CHEP is operated and funded by Hypertension Canada. The members of the CHEP Committee are unpaid volunteers who contribute their time and expertise to the

annual development and dissemination of the CHEP Recommendations. To maintain professional credibility of the content, the process for the development of the recommendations is fully independent and free from external influence. External partners assist with the dissemination of the approved recommendations.

### Disclosures

Lyne Cloutier: honoraria from Merck, and Servier; and research support from Servier. Mark Gelfer: honoraria from Microlife Corp, and PharmaSmart Inc. Lamarre-Cliche, Maxime: advisory committees for Janssen, Takeda, and Forest Laboratories. Milot, Alain: industry-sponsored research funds from AstraZeneca, and Lilly; commercially sponsored continuing medical education events lecture funds from Servier. Raj S. Padwal: research funding from Novo Nordisk, and CVRx; speaking fees from Merck, Abbott, and Servier; consulting fees from Forest Laboratories, and Medtronic. Sheldon W. Tobe: research funds from Abbvie. Guy Tremblay: Advisory Board and Lecturer for Forest Laboratories; consultant for Direction de Santé Publique, -03, La Capitale, SSQ and L'Union-Vie. The remaining authors have no conflicts of interest to disclose.

### References

1. Public Health Agency of Canada. Report form the Canadian Chronic Disease Surveillance System: Hypertension in Canada. Ottawa: Public Health Agency of Canada, 2010.
2. Wilkins K, Campbell NR, Joffres MR, et al. Blood pressure in Canadian adults. *Health Rep* 2010;21:37-46.
3. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2224-60.
4. McAlister FA, Wilkins K, Joffres M, et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. *CMAJ* 2011;183:1007-13.
5. Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Can J Cardiol* 2013;29:528-42.
6. Zarnke KB, Campbell NR, McAlister FA, Levine M. A novel process for updating recommendations for managing hypertension: rationale and methods. *Can J Cardiol* 2000;16:1094-102.
7. Bolli P, Myers M, McKay D. Applying the 2005 Canadian Hypertension Education Program recommendations: 1. Diagnosis of hypertension. *CMAJ* 2005;173:480-3.
8. Hemmelgarn BR, McAllister FA, Myers MG, et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. *Can J Cardiol* 2005;21:645-56.
9. Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. *J Hypertens* 2009;27:280-6.
10. Feldman RD, Campbell N, Larochelle P, et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the

- Development of the 1999 Canadian Recommendations for the Management of Hypertension. *CMAJ* 1999;161(suppl 12):S1-17.
11. Medical Research Council Working Party on Mild to Moderate Hypertension. Randomised controlled trial of treatment for mild hypertension: design and pilot trial. *Br Med J* 1977;1:1437-40.
  12. Howard SC, Rothwell PM. Regression dilution of systolic and diastolic blood pressure in patients with established cerebrovascular disease. *J Clin Epidemiol* 2003;56:1084-91.
  13. Untreated mild hypertension. A report by the Management Committee of the Australian Therapeutic Trial in Mild Hypertension. *Lancet* 1982;1:185-91.
  14. Armitage P, Rose GA. The variability of measurements of casual blood pressure. *Clin Sci* 1966;30:325-35.
  15. Brueren MM, Petri H, Van Weel C, Van Ree JW. How many measurements are necessary in diagnosing mild to moderate hypertension. *Fam Pract* 1997;14:130-5.
  16. Hemmelgarn BR, Zarnke KB, Campbell NR, et al. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis, and assessment of risk. *Can J Cardiol* 2004;20:31-59.
  17. Hartley RM, Velez R, Morris RW, D'Souza MF, Heller RF. Confirming the diagnosis of mild hypertension. *Br Med J (Clin Res Ed)* 1983;286:287-9.
  18. Bovet P, Gervasoni JP, Ross AG, et al. Assessing the prevalence of hypertension in populations: are we doing it right? *J Hypertens* 2003;21:509-17.
  19. Watson RD, Lumb R, Young MA, et al. Variation in cuff blood pressure in untreated outpatients with mild hypertension—implications for initiating antihypertensive treatment. *J Hypertens* 1987;5:207-11.
  20. Jones DW, Appel LJ, Sheps SG, Rocella EJ, Lenfant C. Measuring blood pressure accurately: new and persistent challenges. *JAMA* 2003;289:1027-30.
  21. Armstrong RS. Nurses' knowledge of error in blood pressure measurement technique. *Int J Nurs Pract* 2002;8:118-26.
  22. Gillespie A, Curzio J. Blood pressure measurement: assessing staff knowledge. *Nurs Stand* 1998;12:35-7.
  23. Kemp F, Foster C, McKinlay S. How effective is training for blood pressure measurement? *Prof Nurse* 1994;9:521-4.
  24. Gleichmann SI, Gleichmann UM, Mannebach HJ, Mellwig KP, Philippi HH. Educating nurses in blood pressure measurement and hypertension control. *J Hypertens* 1989;7:S99-102.
  25. Villegas I, Arias IC, Botero A, Escobar A. Evaluation of the technique used by health-care workers for taking blood pressure. *Hypertension* 1995;26:1204-6.
  26. Dreveniorn E, Hakansson A, Petersson K. Blood pressure measurement - an observational study of 21 public health nurses. *J Clin Nurs* 2001;10:189-94.
  27. McKay DW, Campbell NR, Parab LS, Chockalingam A, Fodor JG. Clinical assessment of blood pressure. *J Hum Hypertens* 1990;4:639-45.
  28. McKay DW, Raju MK, Campbell NR. Assessment of blood pressure measuring techniques. *Med Educ* 1992;26:208-12.
  29. Veiga EV, Nogueira MS, Carnio EC, et al. Assessment of the techniques of blood pressure measurement. *Arq Bras Cardiol* 2003;80:89-93.
  30. Rabbia F, Testa E, Rabbia S, et al. Effectiveness of blood pressure educational and evaluation program for the improvement of measurement accuracy among nurses. *High Blood Press Cardiovasc Prev* 2013;20:77-80.
  31. Allaire BT, Trogdon JG, Egan BM, Lackland DT, Masters D. Measuring the impact of a continuing medical education program on patient blood pressure. *J Clin Hypertens* 2011;13:517-22.
  32. Bottenberg MM, Bryant GA, Haack SL, North AM. Assessing pharmacy students' ability to accurately measure blood pressure using a blood pressure simulator arm. *Am J Pharm Educ* 2013;77:1-5.
  33. Dickson BK, Hajjar I. Blood pressure measurement education and evaluation program improves measurement accuracy in community-based nurses: a pilot study. *J Am Acad Nurse Pract* 2007;19:93-102.
  34. Gordon CJ, Frotjold A, Fethney J, et al. The effectiveness of simulation-based blood pressure training in preregistration nursing students. *Simul Healthc* 2013;8:335-40.
  35. Mujtaba SH, Ashraf T, Anjum Q. Improving general practitioners' knowledge regarding blood pressure measurement in selected cities of Pakistan through workshop. *Asia Pac J Public Health* 2013;25:84-91.
  36. Lamarre-Cliche M, Cheong NN, Larochelle P. Comparative assessment of four blood pressure measurement methods in hypertensives. *Can J Cardiol* 2011;27:455-60.
  37. Fagard R, Staessen J, Thijs L, Amery A. Multiple standardized clinic blood pressure may predict left ventricular mass as well as ambulatory monitoring. *American J Hypertens* 1995;8:533-40.
  38. Woodiwiss AJ, Molebatsi N, Maseko MJ, et al. Nurse-recorded auscultatory blood pressure at a single visit predicts target organ changes as well as ambulatory blood pressure. *J Hypertens* 2009;27:287-97.
  39. Myers MG, Valdivieso M, Kiss A. Consistent relationship between automated office blood pressure recorded in different settings. *Blood Press Monit* 2009;14:108-11.
  40. Myers MG, Kaczorowski J, Dawes M, Godwin M. Automated office blood pressure measurement in primary care. *Can Fam Physician* 2014;60:127-32.
  41. Myers MG, Godwin M, Dawes M, et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. *Hypertension* 2010;55:195-200.
  42. Stergiou GS, Parati G, Asmar R, O'Brien E. Requirements for professional office blood pressure monitors. *J Hypertens* 2012;30:537-42.
  43. Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. *BMJ* 2011;342:d286.
  44. Burnier M, Gasser UE. End-digit preference in general practice: a comparison of the conventional auscultatory and electronic oscillometric methods. *Blood Press* 2008;17:104-9.
  45. Ochiai H, Miyazaki N, Miyata T, et al. Assessment of the accuracy of indirect blood pressure measurements. *Jpn Heart J* 1997;38:393-407.
  46. Kollias A, Stergiou GS. Automated measurement of office, home and ambulatory blood pressure in atrial fibrillation. *Clin Exp Pharmacol Physiol* 2014;41:9-15.
  47. Stergiou GS, Kollias A, Karpettas N. Does atrial fibrillation affect the automated oscillometric blood pressure measurement? *Hypertension* 2013;62:e37.



48. Stergiou GS, Kollias A, Destounis A, Tzamouranis D. Automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis. *J Hypertens* 2012;30:2074-82.
49. Myers MG. Replacing manual sphygmomanometers with automated blood pressure measurement in routine clinical practice. *Clin Exp Pharmacol Physiol* 2014;41:46-53.
50. Myers MG. Eliminating the human factor in office blood pressure measurement. *J Clin Hypertens (Greenwich)* 2014;16:541-2.
51. Beckett L, Godwin M. The BpTRU automatic blood pressure monitor compared to 24 hour ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. *BMC Cardiovasc Disord* 2005;5:18.
52. Myers MG. A proposed algorithm for diagnosing hypertension using automated office blood pressure measurement. *J Hypertens* 2010;28:703-8.
53. Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. *Fam Pract* 2012;29:376-82.
54. Godwin M, Birtwhistle R, Delva D, et al. Manual and automated office measurements in relation to awake ambulatory blood pressure monitoring. *Fam Pract* 2011;28:110-7.
55. Rabi DM, Daskalopoulou SS, Padwal RS, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. *Can J Cardiol* 2011;27:415-433.e1-2.
56. Andreadis EA, Agaliotis GD, Angelopoulos ET, et al. Automated office blood pressure and 24-h ambulatory measurements are equally associated with left ventricular mass index. *Am J Hypertens* 2011;24:661-6.
57. Andreadis EA, Agaliotis GD, Angelopoulos ET, et al. Automated office blood pressure is associated with urine albumin excretion in hypertensive subjects. *Am J Hypertens* 2012;25:969-73.
58. Campbell NR, McKay DW, Conradson H, et al. Automated oscillometric blood pressure versus auscultatory blood pressure as a predictor of carotid intima-medial thickness in male firefighters. *J Hum Hypertens* 2007;21:588-90.
59. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. *J Hypertens* 2007;25:2193-8.
60. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. *J Hypertens* 2013;31:1731-68.
61. Franklin SS, Thijs L, Hansen TW, O'Brien E, Staessen JA. White-coat hypertension: new insights from recent studies. *Hypertension* 2013;62:982-7.
62. Ben-Dov IZ, Ben-Arie L, Mekler J, Bursztyn M. Reproducibility of white-coat and masked hypertension in ambulatory BP monitoring. *Int J Cardiol* 2007;117:355-9.
63. Muxfeldt ES, Fiszman R, de Souza F, et al. Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. *Hypertension* 2012;59:384-9.
64. Verberk WJ, Kroon AA, Thien T, et al. Prevalence of the white-coat effect at multiple visits before and during treatment. *J Hypertens* 2006;24:2357-63.
65. Hansen TW, Kikuya M, Thijs L, et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7030 individuals. *J Hypertens* 2007;25:1554-64.
66. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. *Hypertension* 2005;45:203-8.
67. Stergiou GS, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. *Hypertension* 2014;63:675-82.
68. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. *Hypertension* 2009;54:226-32.
69. Ugajin T, Hozawa A, Ohkubo T, et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. *Arch Int Med* 2005;165:1541-6.
70. Kollias A, Ntineri A, Stergiou GS. Is white-coat hypertension a harbinger of increased risk? *Hypertens Res* 2014;37:791-5.
71. Campbell NR, Culleton BW, McKay D. Misclassification of blood pressure by usual measurement in ambulatory physician practices. *Am J Hypertens* 2005;18:1522-7.
72. Kay LE. Accuracy of blood pressure measurement in the family practice center. *J Am Board Fam Prac* 1998;11:252-8.
73. Robitaille C, Dai S, Waters C, et al. Diagnosed hypertension in Canada: incidence, prevalence and associated mortality. *CMAJ* 2012;184:E49-56.
74. Pickering TG, Levenstein M, Walmsley P. Differential effects of doxazosin on clinic and ambulatory pressure according to age, gender, and presence of white coat hypertension. Results of the HALT Study. Hypertension and Lipid Trial Study Group. *Am J Hypertens* 1994;7:848-52.
75. Pickering TG. White coat hypertension. *Curr Opin Nephrol Hypertens* 1996;5:192-8.
76. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Circulation* 2000;102:1139-44.
77. Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). *Circulation* 2001;104:1385-92.
78. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. *Hypertension* 2005;46:156-61.
79. Niiranen TJ, Hanninen MR, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. *Hypertension* 2010;55:1346-51.
80. Asayama K, Ohkubo T, Kikuya M, et al. Use of 2003 European Society of Hypertension-European Society of Cardiology guidelines for predicting stroke using self-measured blood pressure at home: the Ohasama study. *Eur Heart J* 2005;26:2026-31.
81. Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurements has a stronger predictive power for mortality than does screening blood pressure measurements: a population-based observation in Ohasama, Japan. *J Hypertens* 1998;16:971-5.
82. Bobrie G, Genès N, Vaur L, et al. Is "isolated home" hypertension as opposed to "isolated office" hypertension a sign of greater cardiovascular risk? *Arch Int Med* 2001;161:2205-11.

83. Stergiou GS, Siontis KC, Ioannidis JP. Home blood pressure as a cardiovascular outcome predictor: it's time to take this method seriously. *Hypertension* 2010;55:1301-3.
84. Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. *J Hypertens* 2008;26:1290-9.
85. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. *Lancet* 2007;370:1219-29.
86. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. *Hypertension* 2008;51:55-61.
87. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. *J Hypertens* 2012;30:449-56.
88. Hodgkinson J, Mant J, Martin U, et al. Relative effectiveness of clinic and home blood pressure monitoring compared with ambulatory blood pressure monitoring in diagnosis of hypertension: systematic review. *BMJ* 2011;342:d3621.
89. Stergiou GS, Kollias A, Zeniodi M, Karpettas N, Ntineri A. Home blood pressure monitoring: primary role in hypertension management. *Curr Hypertens Rep* 2014;16:462.
90. Hara A, Tanaka K, Ohkubo T, et al. Ambulatory versus home versus clinic blood pressure: the association with subclinical cerebrovascular diseases: the Ohasama Study. *Hypertension* 2012;59:22-8.
91. Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. *J Hypertens* 2012;30:1289-99.
92. Warren RE, Marshall T, Padfield PL, Chrubasik S. Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements. *Br J Gen Pract* 2010;60:675-80.
93. Bobrie G, Chatellier G, Genès N, et al. Cardiovascular prognosis of "Masked Hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. *JAMA* 2004;291:1342-9.
94. Coll de Tuero G, Llibre JB, Poncelas AR, et al. Isolated clinical hypertension diagnosis: self-home BP, ambulatory BP monitoring, or both simultaneously? *Blood Press Monit* 2011;16:11-5.
95. Stergiou GS, Bliziotis IA. Home blood pressure monitoring in the diagnosis and treatment of hypertension: a systematic review. *Am J Hypertens* 2011;24:123-34.
96. Wang YC, Koval AM, Nakamura M, et al. Cost-effectiveness of secondary screening modalities for hypertension. *Blood Press Monit* 2013;18:1-7.
97. Lorgelly P, Siatis I, Brooks A, et al. Is ambulatory blood pressure monitoring cost-effective in the routine surveillance of treated hypertensive patients in primary care? *Br J Gen Pract* 2003;53:794-6.
98. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. *Lancet* 2011;378:1219-30.
99. National Clinical Guideline Center. Hypertension: the Clinical Management of Primary Hypertension in Adults. London: Royal College of Physicians, 2011.
100. Health Quality Ontario. Twenty-four-hour ambulatory blood pressure monitoring in hypertension: an evidence-based analysis. *Ont Health Technol Assess Ser* 2012;12:1-65.
101. Hansen TW, Li Y, Boggia J, et al. Predictive role of the nighttime blood pressure. *Hypertension* 2011;57:3-10.
102. Fan HQ, Li Y, Thijs L, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. *J Hypertens* 2010;28:2036-45.
103. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. *J Am Coll Cardiol* 2011;58:1165-73.
104. Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. Ambulatory blood pressure monitoring: importance of sampling rate and duration—48 versus 24 hours—on the accurate assessment of cardiovascular risk. *Chronobiol Int* 2013;30:55-67.
105. Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. *Lancet* 2012;379:905-14.
106. Björklund K, Lind L, Zethelius B, Berglund L, Lithell H. Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men. *J Hypertens* 2004;22:1691-7.
107. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. *N Engl J Med* 2003;348:2407-15.
108. Fagard RH, Thijs L, Staessen JA, et al. Prognostic significance of ambulatory blood pressure in hypertensive patients with history of cardiovascular disease. *Blood Press Monit* 2008;13:325-32.
109. Khattar RS, Swales JD, Dore C, Senior R, Lahiri A. Effect of aging on the prognostic significance of ambulatory systolic, diastolic, and pulse pressure in essential hypertension. *Circulation* 2001;104:783-9.
110. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. *Hypertension* 2006;47:846-53.
111. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. *J Am Coll Cardiol* 2005;46:508-15.
112. Pickering T, Schwartz J, Verdecchia P, et al. Prediction of strokes versus cardiac events by ambulatory monitoring of blood pressure: results from an international database. *Blood Press Monit* 2007;12:397-9.
113. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory home blood pressures compared with office blood pressure in the general population. *Circulation* 2005;111:1777-83.
114. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. *JAMA* 1999;282:539-46.
115. Hansens TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure and mortality: a population-based study. *Hypertension* 2005;45:499-504.
116. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Ambulatory blood pressure thresholds for diagnosis of hypertension in patients with and without type 2 diabetes based on cardiovascular outcomes. *Chronobiol Int* 2013;30:132-44.
117. Cuspidi C, Meani S, Fusi V, et al. Home blood pressure measurement and its relationship with blood pressure control in a large selected hypertensive population. *J Hum Hypertens* 2004;18:725-31.

118. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. *Ann Int Med* 2013;159:185-94.
119. Marquez-Contreras E, Martell-Claros N, Gil-Guillen V, et al. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. *J Hypertens* 2006;24:169-75.
120. Viera AJ, Cohen LW, Mitchell CM, Sloane PD. How and why do patients use home blood pressure monitors? *Blood Press Monit* 2008;13:133-7.
121. Lopez LM, Taylor JR. Home blood pressure monitoring: point-of-care testing. *Ann Pharmacother* 2004;38:868-73.
122. Yarows SA, Julius S, Pickering TG. Home blood pressure monitoring. *Arch Int Med* 2000;160:1251-7.
123. Leblanc ME, Cloutier L, Veiga EV. Knowledge and practice outcomes after home blood pressure measurement education programs. *Blood Press Monit* 2011;16:265-9.
124. Bloom KC, Farina S, Gomez YH, et al. MEthods of ASsessing blood pressUre: identifying thReshold and target valuEs (MeasureBP): a review and study protocol. *Curr Hypertens Rep* 2015;17:533.
125. Dickson RC, Gaebel K, Zizzo A, et al. Self-reported physician adherence to guidelines for measuring blood pressure. *J Am Board Fam Med* 2013;26:215-7.